| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9917688 | European Journal of Pharmaceutical Sciences | 2005 | 6 Pages |
Abstract
Lumiracoxib readily enters the air pouch and persists in this extravascular compartment for a longer period of time than in plasma. This distribution profile may contribute to the ability of lumiracoxib to inhibit PGE2 production up to 24Â h after dosing.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Ronald E. Esser, Rocca Miserendino-Molteni, Michele Sharr, Xiaoli Zhang, Wilma Porter, Luis Ramos, Jeffrey A. Cramer, Shumin Zhuang, Anna Georgieva, Wieslawa Maniara,